» Articles » PMID: 15076623

Irreversible Intestinal Failure

Overview
Publisher Wiley
Date 2004 Apr 13
PMID 15076623
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Intestinal failure (IF) can be defined as the reduction of functional gut mass below the minimal amount necessary for digestion and absorption adequate to satisfy the nutrient and fluid requirements for maintenance in adults or growth in children. In developed countries, IF mainly includes individuals with the congenital or early onset of conditions requiring protracted or indefinite parenteral nutrition (PN). Short bowel syndrome was the first commonly recognized cause of protracted IF. The normal physiologic process of intestinal adaptation after extensive resection usually allows for recovery of sufficient intestinal function within weeks to months. During this time, patients can be sustained on parenteral nutrition. Only a few children have permanent intestinal insufficiency and life-long dependency on PN. Non-transplant surgery including small bowel tapering and lengthening may allow weaning from PN in some cases. Hormonal therapy with recombinant human growth hormone has produced poor results while therapy with glucagon-like peptide-2 holds promise. Congenital diseases of enterocyte development such as microvillus inclusion disease or intestinal epithelial dysplasia cause permanent IF for which no curative medical treatment is currently available. Severe and extensive motility disorders such as total or subtotal intestinal aganglionosis (long segment Hirschsprung disease) or chronic intestinal pseudo-obstruction syndrome may also cause permanent IF. PN and home-PN remain are the mainstays of therapy regardless of the cause of IF. Some patients develop complications while receiving long-term PN for IF especially catheter related complications (thrombosis, sepsis) and liver disease. These patients may be candidates for intestinal transplantation. This review discusses the causes of irreversible IF and emphasizes the specific medico-surgical strategies for prevention and treatment of these conditions at several stages of IF.

Citing Articles

Ellagic acid alleviates DSS-induced ulcerative colitis by inhibiting ROS/NLRP3 pathway activation and modulating gut microbiota in mice.

Xiong Y, Cheng Z, Zhang Y, Liu T, Wan Z, Xia C Eur J Nutr. 2025; 64(1):64.

PMID: 39775279 DOI: 10.1007/s00394-024-03577-7.


Bovine Colostrum in Pediatric Nutrition and Health.

Canbolat A, Lombardo M, Mondragon A, Lopez J, Bechelany M, Karav S Nutrients. 2025; 16(24.

PMID: 39770926 PMC: 11677144. DOI: 10.3390/nu16244305.


Bioengineering of Intestinal Grafts.

Herath M, Speer A Gastroenterol Clin North Am. 2024; 53(3):461-472.

PMID: 39068007 PMC: 11284275. DOI: 10.1016/j.gtc.2023.12.006.


Administration of 4% tetrasodium EDTA lock solution and central venous catheter complications in high-risk pediatric patients with intestinal failure: A retrospective cohort study.

Hirsch T, Fligor S, Tsikis S, Mitchell P, Devietro A, Carbeau S JPEN J Parenter Enteral Nutr. 2024; 48(5):624-632.

PMID: 38837803 PMC: 11216891. DOI: 10.1002/jpen.2644.


From intestinal failure to transplantation: Review on the current need for transplant indications under multidisciplinary transplant programs worldwide.

Raghu V, Rumbo C, Horslen S Pediatr Transplant. 2024; 28(3):e14756.

PMID: 38623905 PMC: 11115375. DOI: 10.1111/petr.14756.